Gold, Ralf
Radue, Ernst-Wilhelm
Giovannoni, Gavin
Selmaj, Krzysztof
Havrdova, Eva Kubala
Montalban, Xavier
Stefoski, Dusan
Sprenger, Till
Robinson, Randy R.
Fam, Sami
Smith, Jonathan
Chalkias, Spyros
Giannattasio, Giorgio
Lima, Gabriel
Castro-Borrero, Wanda
Funding for this research was provided by:
Biogen
AbbVie
Article History
Received: 12 December 2019
Revised: 9 April 2020
Accepted: 9 April 2020
First Online: 25 May 2020
Compliance with ethical standards
:
: RG: consulting fees from Bayer, Biogen, Merck Serono, Novartis, Sanofi-Aventis, and Teva; editor of <i>Therapeutic Advances in Neurological Disorders</i>; research support from Biogen, Genzyme, Merck Serono, Novartis, and Teva; E-WR: speaker fees from Actelion, Basilea, Bayer, Biogen, Merck Serono, and Novartis; research support from Actelion, Bayer, Biogen, Merck Serono, and Novartis; GGiovannoni: advisory boards for AbbVie Inc., Almirall, Atara, Biogen, Canbex, Ironwood, Merck, Merck Serono, Novartis, Roche, Sanofi-Genzyme, Synthon, Teva, and Vertex; speaker fees from AbbVie, Biogen, Bayer, Genzyme, Merck Serono, Sanofi-Aventis, and Teva; co-editor in chief of <i>Multiple Sclerosis and Related Disorders</i>; research support unrelated to study from Biogen, Genzyme, Ironwood, Merck Serono, and Novartis; KS: consulting fees from Genzyme, Novartis, Ono, Roche, Synthon, and Teva; speaker fees from Biogen; EKH: honoraria/research support from Actelion, Biogen, Celgene, Genzyme, Merck Serono, Novartis, Roche, and Teva; advisory boards for Actelion, Biogen, Celgene, Genzyme, Merck Serono, Novartis, and Roche; supported by the Czech Ministry of Education research project PROGRES Q27/LF1; XM: speaker fees/travel expense reimbursement from and steering committee/advisory boards for Actelion, Almirall, Bayer, Biogen, Genzyme, Merck, Neurotec, Novartis, Octapharma, Receptos, Roche, Sanofi-Aventis, Teva, and Trophos; DS: consulting fees from Acorda, Biogen, Serono, and Teva; speaker fees from Acorda, Biogen, Elan, EMD Serono, and Teva; royalty payments of licensed drug from Acorda; research support from Biogen, Novartis, Pfizer, and Serono; TS: speaker/advisory board fees paid to previous (University Hospital Basel) and current (DKD Helios Klinik Wiesbaden) employer from Actelion, ATI, Biogen, Desitin, electroCore, Lilly, Merck Serono, Mitsubishi, Novartis, Sanofi-Genzyme, Roche, and/or Teva; research grants from EFIC GrĂĽnenthal, Novartis, Swiss Multiple Sclerosis Society, and Swiss National Science Foundation; RRR: employee of and holds stock/stock options in AbbVie; SF, JS, SC, and WC-B: employees of and hold stock/stock options in Biogen; GGiannattasio: former employee of Biogen; GL: former employee of and holds stock/stock options in Biogen.
: All patients provided written informed consent to participate in the SELECT, SELECTION, and SELECTED studies.
: The SELECTED protocol was approved by central and local ethics committees, and the study was conducted in accordance with the International Conference on Harmonization Guideline for Good Clinical Practice and the Declaration of Helsinki. A full listing of Ethics Committees who approved the study is available in Table S1 in Gold et al. [CitationRef removed].
: Requests for data supporting this manuscript should be submitted to the Biogen Clinical Data Request Portal (ExternalRef removed).